ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

0G8X Immunovia Ab (publ)

191.40
0.00 (0.00%)
17 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Immunovia Ab (publ) LSE:0G8X London Ordinary Share SE0006091997 IMMUNOVIA ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 191.40 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Surgical,med Instr,apparatus 1.8M -309.44M -6.8328 -0.02 6.79M

Change in number of shares and votes in Immunovia AB (publ)

31/05/2023 11:16am

PR Newswire (US)


Immunovia Ab (publ) (LSE:0G8X)
Historical Stock Chart


From May 2023 to May 2024

Click Here for more Immunovia Ab (publ) Charts.

LUND, Sweden, May 31, 2023 /PRNewswire/ -- The number of shares and votes in Immunovia AB (publ) ("Immunovia") have changed as a result of new shares being issued in the rights issue resolved by the board of directors on 20 February 2023, subject to approval from the extraordinary general meeting on 16 March 2023. 

Through the rights issue, the number of outstanding shares and votes have increased by 22,655,917, from 22,631,581 to 45,287,498. The share capital has increased by SEK 1,132,795.85, from SEK 1,131,579.05 to SEK 2,264,374.90.

For more information, please contact:
Karin Almqvist Liwendahl
CFO
kain.almqvist.liwendahl@immunovia.com
+46 70 911 56 08

The information was submitted for publication, through the agency of the contact person set out above, at 11:45 CET on 31 May 2023. 

About Immunovia
Immunovia is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. 

Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com. 

Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups.  

The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world's largest market for the detection of pancreatic cancer with an estimated, addressable market size of 1.8 million individuals per year who could benefit from our test. 

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com 

The following files are available for download:

https://mb.cision.com/Main/13121/3777774/2096139.pdf

Press release (PDF)

 

Cision View original content:https://www.prnewswire.co.uk/news-releases/change-in-number-of-shares-and-votes-in-immunovia-ab-publ-301838450.html

Copyright 2023 PR Newswire

1 Year Immunovia Ab (publ) Chart

1 Year Immunovia Ab (publ) Chart

1 Month Immunovia Ab (publ) Chart

1 Month Immunovia Ab (publ) Chart